📰 Interim Safety News

Interim Safety News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Interim Safety. Real-time updates on events, politics, business and more.

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

October 19, 2023

Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 -- Pliant Therapeutics, Inc. , a clinical-stage...

United States Johanna Schaub Christopher Keenan Michael Trauner Richard Pencek Terry Horner

Source: marketscreener.com

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical's Proprietary Suprachoroidal Space Platform Seite 1

October 4, 2022

04.10.2022 - - Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector - - SCS Microinjector Featured in Multiple Oral and Poster ... Seite 1

United States Thomasa Ciulla Development Officer Aura Biosciences Inc Suprachoroidal Administration Drug Administration

Source: wallstreet-online.de

Biogen Inc.: New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression

April 4, 2022

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high

United States United Kingdom Maha Radhakrishnan Charles Weissmann Walter Gilbert Heinz Schaller

Source: finanznachrichten.de

New Data at AAN 2022 Highlight Real-World Evidence from

April 4, 2022

Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every...

United States United Kingdom Maha Radhakrishnan Charles Weissmann Walter Gilbert Heinz Schaller

Source: globenewswire.com

Biogen Inc.: New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

October 13, 2021

MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccinationData from this analysis also suggest

United Kingdom United States Jeffrey Cohen Maha Radhakrishnan Walter Gilbert Charles Weissmann

Source: finanznachrichten.de

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation